Skip to main content
Home

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Home

Main navigation InfoLep

  • Leprosy [5]
    • Global and Regional Leprosy Situation
    • WHO Global Leprosy Strategy
    • ILEP Strategy
    • World Leprosy Day
    • Leprosy journals
  • Key topics [7]
    • Leprosy and COVID-19
    • Diagnostic tests
    • Prevention of leprosy [2]
      • Interventions to reduce transmission: post-exposure prophylaxis (PEP) [3]
        • LPEP Programme
        • PEP++ project
        • PEP4LEP project
      • Interventions to reduce transmission: vaccines
    • Rehabilitation & prevention of disability [2]
      • Preventing leprosy-related disabilities in girls and boys
      • Self-care in leprosy
    • Leprosy Antibiotic Treatment
    • Stigma, discrimination & mental wellbeing [4]
      • World Leprosy Day 2022
      • Gender
      • Mental wellbeing
      • SARI Project
    • Bioarchaeology of leprosy
  • Toolkits [6]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • Perception Study Toolkit (PST)
    • Zero Leprosy Toolkit
    • CBM's Community Mental Health Good Practice Guides
    • GPZL & Infolep Factsheets
  • Online courses
  • Ocular DB

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Visit our e-learning platform
Search resources Search in Practical Materials, Publications, Organizations, Online Course and more
Publication

ÁREAS PRIORITÁRIAS PARA CONTROLE DA HANSENÍASE NO MUNICÍPIO DE JABOATÃO DOS GUARARAPES, PERNAMBUCO, BRASIL, 2017

Carneiro GR, Francisco MM, Oliveira ALDSD, et al. Atena Editora. Condições Teórico-Práticas das Ciências da Saúde no Brasil. 2020;
Download PDF
Publication

A randomized controlled trial of prednisolone vs TNF-alfa inhibitor Infliximab in the management of type 1 lepra reaction in leprosy patients

Mitra D. Elsevier BV. International Journal of Infectious Diseases. 2020;
Publication

Randomized control trial to evaluate the clinical and cytokine response profile to oral thalidomide in leprosy patients with erythema nodosum leprosum

Mitra B. Elsevier BV. International Journal of Infectious Diseases. 2020;
Publication

Association of Testosterone Level among Lepromatous and Borderline Leprosy Male Patients: Experience of 30 Cases in Bangladesh

Mohammad AS, Mia T, Hamid M, et al. Bangladesh Journals Online (JOL). Bangladesh Journal of Infectious Diseases. 2021; 7 (2) : 36-39.
Publication

IL-6 promotes pathogenic Th17 in T1R leprosy reactions by stimulating Il17 producing by IL-6R pathway

Saini C, Srivastava R, Khanna N, et al. Elsevier BV. International Journal of Infectious Diseases. 2020;
Publication

Serum immune markers as triggers of reactional episodes in multibacillary patients with leprosy

Rêgo JL, Santana NDL, Aguiar ER, et al. Lepra. Leprosy Review. 2020; 91 (4) : 393-402.
Download PDF
Publication

Exploring the Dimensions of Health-related Stigma: Insights from narratives of people with stigmatized health conditions in Indonesia

Rai S. VU University. 2021;
Download PDF
Publication

Soluble mediators of immune significance in sera of leprosy patients

Dubey A, Gaur R, Arela N, et al. Lepra. Leprosy Review. 2020; 91 (4) : 403-412.
Download PDF
Publication

PERFIL CLÍNICO-NEUROLÓGICO DE PACIENTES COM HANSENÍASE

Neto MPL, Cunha FMBD, Gonçalves HDS, et al. Atena Editora. Frente Diagnóstica e Terapêutica na Neurologia 3. 2021;
Download PDF
Publication

Novartis renews WHO medicine donation pledge with aim of ending leprosy

Novartis . 2021;
Download PDF

Pagination

  • Previous page ‹‹
  • Page 300
  • Next page ››
Subscribe to Full text online

Quick links

  • Leprosy
  • Key topics
  • Toolbox
  • Publications

Support

  • Contact
  • Privacy statement
  • Contact
  • FAQ

Contact us

info@infolep.org

(+31) 20 595 0500

     

Stay up to date with the latest publications and news related to leprosy.

Subscribe to newsletter

Related websites:

© 2025 InfoNTD